Core Viewpoint - Zhejiang Haisheng Medical Equipment Co., Ltd. (stock code: 920166.BJ) was listed on the Beijing Stock Exchange, closing at 34.49 yuan with a significant increase of 172.86% on the first day of trading, indicating strong market interest and investor confidence in the company’s growth potential [1]. Company Overview - Haisheng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in various clinical settings such as anesthesia, ICU, and emergency departments [1]. - The company is controlled by Huang Haisheng and Wu Xiaoye, who collectively hold 54.92% of the shares, establishing them as the actual controllers of the company [1]. Financial Information - The company raised a total of 142.76 million yuan in its public offering, with a net amount of 113.44 million yuan after expenses, which was 25.70 million yuan less than initially planned [3]. - The financial performance from 2022 to mid-2025 shows a steady increase in revenue, with figures of 26.77 million yuan, 30.59 million yuan, 30.37 million yuan, and 15.56 million yuan for the respective periods [5]. - Net profit attributable to the parent company for the same periods was 7.01 million yuan, 7.80 million yuan, 7.09 million yuan, and 3.55 million yuan, indicating a relatively stable profit margin [5]. Project Funding and Allocation - The funds raised will be allocated to three main projects: upgrading and expanding production of anesthesia and emergency medical devices (24.84 million yuan), establishing a research and testing center (17.67 million yuan), and building a marketing service base (5.76 million yuan) [4]. - The total estimated investment for these projects is 48.27 million yuan, with the planned use of raised funds amounting to 37.04 million yuan [4]. Market and Policy Considerations - The company is subject to industry policies such as volume-based procurement and the "two-invoice system," which may impact its operational stability and performance [2]. - The company is expected to address these policy impacts and outline its strategies in future disclosures [2].